218 related articles for article (PubMed ID: 10478664)
1. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations.
Moinfar F; Man YG; Lininger RA; Bodian C; Tavassoli FA
Am J Surg Pathol; 1999 Sep; 23(9):1048-58. PubMed ID: 10478664
[TBL] [Abstract][Full Text] [Related]
2. Spindle cell ductal carcinoma in situ. An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation.
Farshid G; Moinfar F; Meredith DJ; Peiterse S; Tavassoli FA
Virchows Arch; 2001 Jul; 439(1):70-7. PubMed ID: 11499843
[TBL] [Abstract][Full Text] [Related]
3. Large-needle core biopsy in atypical intraductal epithelial hyperplasia including immunohistochemical expression of high molecular weight cytokeratin: analysis of results of a single institution.
Gal-Gombos EC; Esserman LE; Recine MA; Poppiti RJ
Breast J; 2002; 8(5):269-74. PubMed ID: 12199753
[TBL] [Abstract][Full Text] [Related]
4. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.
Lacroix-Triki M; Mery E; Voigt JJ; Istier L; Rochaix P
Virchows Arch; 2003 Jun; 442(6):548-54. PubMed ID: 12712335
[TBL] [Abstract][Full Text] [Related]
5. Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast.
Raju U; Crissman JD; Zarbo RJ; Gottlieb C
Am J Surg Pathol; 1990 Oct; 14(10):939-47. PubMed ID: 1698341
[TBL] [Abstract][Full Text] [Related]
6. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia.
Tavassoli FA
Mod Pathol; 1998 Feb; 11(2):140-54. PubMed ID: 9504685
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast.
Otterbach F; Bànkfalvi A; Bergner S; Decker T; Krech R; Boecker W
Histopathology; 2000 Sep; 37(3):232-40. PubMed ID: 10971699
[TBL] [Abstract][Full Text] [Related]
9. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias.
Bratthauer GL; Moinfar F; Stamatakos MD; Mezzetti TP; Shekitka KM; Man YG; Tavassoli FA
Hum Pathol; 2002 Jun; 33(6):620-7. PubMed ID: 12152161
[TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of 34 betaE 12 in differential diagnosis of benign and malignant mammary lesions].
Di F; Wong NL
Zhonghua Bing Li Xue Za Zhi; 2004 Feb; 33(1):31-5. PubMed ID: 14989925
[TBL] [Abstract][Full Text] [Related]
11. Ductal intraepithelial neoplasia (IDH, AIDH and DCIS).
Tavassoli FA
Breast Cancer; 2000; 7(4):315-20. PubMed ID: 11114857
[No Abstract] [Full Text] [Related]
12. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
[TBL] [Abstract][Full Text] [Related]
13. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
14. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
Yang G; Guo L; Jin H; Li J; Ding H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
[TBL] [Abstract][Full Text] [Related]
16. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin immunoreactivity in lobular intraepithelial neoplasia.
Bratthauer GL; Miettinen M; Tavassoli FA
J Histochem Cytochem; 2003 Nov; 51(11):1527-31. PubMed ID: 14566024
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical analysis of p63 and 34βE12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinoma in situ.
Hoshikawa S; Sano T; Hirato J; Oyama T; Fukuda T
Cytopathology; 2016 Apr; 27(2):108-14. PubMed ID: 25810244
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast.
Tavassoli FA; Norris HJ
Cancer; 1990 Feb; 65(3):518-29. PubMed ID: 2297643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
